Plum SEC

Korean Market
Privacy Policy

Korean Market

Reset (View All)
★★★★★
★★★★
★★★
★★
★
★
★
★★
★★★
★★★★
★★★★★

All Disclosures

PERI

ABL Bio

★★★

ABL Bio reports Q1 2026 revenue of KRW 13.1B; major licensing deals with GSK and Lilly drive growth outlook

05/08/2026, 05:35 PM

한국어 | English | 中文 | 日本語

Plum SEC © 2026.05.25

The information provided on this site is for reference only and we do not guarantee its accuracy or completeness. Users are solely responsible for any investment decisions made based on this information.